Bausch & Lomb Corp (New York Stock Exchange:BLCO)
| Market Cap | 6.11B+16.2% |
| Revenue (ttm) | 5.32B+8.8% |
| Net Income | -171.00M+37.4% |
| EPS | -0.48+38.5% |
| Shares Out | 357.17M |
| PE Ratio | n/a |
| Forward PE | 15.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44,765 |
| Open | 17.50 |
| Previous Close | 17.34 |
| Day's Range | 17.08 - 17.50 |
| 52-Week Range | 13.77 - 18.92 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 20.83(+21.85%) |
| Earnings Date | Oct 28, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About BLCO
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$BLCO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BLCO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BLCO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BLCO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BLCO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BLCO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BLCO
| ETF | Est. Holding Size |
|---|---|
| MGMTBallast Small/Mid Cap ETF | $2.44M |
| DFAXDimensional World ex U.S. Core Equity 2 ETF | $263.26K |
| PDNInvesco RAFI Developed Markets ex-U.S. Small-Mid ETF | $157.56K |
| GVLUGotham 1000 Value ETF | $104.95K |
| DFICDimensional - International Core Equity 2 ETF | $44.36K |
| BKSEBNY Mellon US Small Cap Core Equity ETF | $28.89K |
Estimated from each fund’s disclosed top holdings × AUM
BLCO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BLCO’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score